BPC-157 vs LL-37: Tissue Repair vs Antimicrobial Peptide Comparison | Peptpedia

BPC-157 promotes tissue repair through multiple mechanisms: upregulation of growth hormone receptors in fibroblasts (amplifying their response to healing signals), activation of the FAK-paxillin pathway (promoting cell adhesion and migration), modulation of the nitric oxide system (enhancing vascular function and blood flow), and dual activation of the Egr-1/NAB2 gene loop (driving organized angiogenesis). These mechanisms are particularly relevant to tendon, muscle, gut mucosal, and skin repair in animal models.

LL-37 functions as both a direct antimicrobial and an immune signaling peptide. As a cationic amphipathic helix, it disrupts bacterial cell membranes through electrostatic interaction. Beyond killing, it activates formyl peptide receptor 2 (FPR2) on immune cells, recruits and activates neutrophils and macrophages, stimulates keratinocyte migration for wound re-epithelialization, and promotes angiogenesis through VEGF upregulation. Its role in wound healing bridges innate immunity and tissue repair.

BPC-157 is a synthetic gastric pentadecapeptide (15 amino acids) that promotes tissue repair through nitric oxide (NO) system modulation, VEGF-driven angiogenesis, and upregulation of growth hormone receptors in fibroblasts. It acts as a systemic repair signal — studies demonstrate efficacy across anatomically distant injury sites (gut, tendon, muscle, nerve, bone) following both local and systemic administration. Its cytoprotective effects span the entire gastrointestinal tract in preclinical models, and it counteracts organ damage induced by NSAIDs, alcohol, and surgical insult.

LL-37 is the sole human cathelicidin antimicrobial peptide, a 37-amino-acid fragment cleaved from the precursor protein hCAP18 by proteinase 3. Its primary antimicrobial mechanism involves direct bacterial membrane disruption through electrostatic interaction between its cationic amphipathic alpha-helix and negatively charged microbial phospholipids. Beyond direct killing, LL-37 modulates immune responses through formyl peptide receptor 2 (FPR2) signaling on neutrophils and macrophages, triggering chemotaxis, degranulation, and cytokine production. This dual antimicrobial/immunomodulatory profile makes LL-37 a bridge between innate immunity and adaptive wound defense.

BPC-157 research focuses on musculoskeletal repair (tendon, ligament, muscle), gastrointestinal protection (ulcer models, IBD models), and wound healing acceleration. In Achilles tendon transection models, BPC-157 restored biomechanical strength to near-baseline values. In NSAID-induced gastropathy models, it prevented and reversed mucosal damage dose-dependently. The wound healing literature demonstrates accelerated collagen deposition, organized angiogenesis, and faster granulation tissue formation. All BPC-157 evidence remains preclinical — no completed randomized controlled human trials exist as of 2026.

LL-37 research spans wound infection defense, antimicrobial activity against drug-resistant organisms (including MRSA and Pseudomonas aeruginosa), and inflammatory bowel disease pathophysiology. Critically, LL-37 is one of the few antimicrobial peptides with Phase 1-2 human clinical trial data: a randomized trial of topical LL-37 for chronic venous leg ulcers demonstrated significantly improved healing rates and wound closure compared to placebo, with acceptable safety (PMID 25041740). This positions LL-37 ahead of most antimicrobial peptides in clinical translation for wound care applications.

BPC-157 and LL-37 target complementary aspects of tissue healing. BPC-157 drives the repair cascade — angiogenesis, collagen synthesis, fibroblast migration, and growth factor receptor upregulation — essentially rebuilding damaged tissue architecture. LL-37 addresses the infection and inflammation component — killing invading bacteria, recruiting immune cells, and signaling keratinocyte migration for wound surface closure.

BPC-157 has the larger preclinical evidence base, with over 100 published studies spanning tendon, muscle, gut, nerve, bone, and vascular tissue repair. LL-37 has the advantage of human clinical trial data (Phase 1-2 for venous leg ulcers), placing it further along the translational pipeline for wound care specifically. No published research has evaluated their combination, though the non-overlapping mechanisms (structural repair vs. antimicrobial defense) provide a clear theoretical rationale for complementary use in wound healing research.